Related Experiment Video
Updated: May 22, 2026

A Novel Surgical Technique in a Sheep Model for Suburethral Graft Implantation
Published on: June 20, 2025
Periurethral abscess following polyacrylamide hydrogel (Bulkamid) for stress urinary incontinence
D Gopinath1, A R B Smith, F M Reid
1Warrell unit, St Mary's Hospital, Manchester M13 9WL, UK. DEEPS781@HOTMAIL.COM
Abstract:
Bulkamid is a periurethral bulking agent used to treat stress urinary incontinence (SUI). Manufacturers describe it as nontoxic, nonbiodegradable and biocompatible. Periurethral abscesses are one of the known complications of bulking agents. We present the first reported case of periurethral abscess following Bulkamid injection. The woman had previously had a transobturator tape (TOT) and total vaginal mesh repair. At 6 weeks after injection of the bulking agent, she reported 100 % cure of her SUI. Transperineal ultrasound was used to diagnose and monitor an abscess that developed anterior and lateral to the urethra and separate from the TOT. Magnetic resonance imaging was helpful in delineating the extent of the abscess into the retropubic space but was not able to identify the urethra or the TOT. Surgical drainage of the abscess was performed vaginally, resulting in successful resolution of pain but recurrence of incontinence.
Insights
This case report details the first instance of a periurethral abscess after Bulkamid injection for stress urinary incontinence (SUI). While initially successful, the complication required surgical drainage, leading to recurrent SUI.
Area of Science:
- Urology
- Gynecology
- Medical Device Complications
Background:
- Bulkamid is a periurethral bulking agent for stress urinary incontinence (SUI).
- Periurethral abscesses are a known complication of bulking agents.
- This study presents the first reported case of a periurethral abscess following Bulkamid injection.
Observation:
- A patient with prior transobturator tape (TOT) and vaginal mesh repair received Bulkamid for SUI.
- The patient reported complete SUI cure at 6 weeks post-injection.
- A periurethral abscess developed, diagnosed and monitored via transperineal ultrasound.
Findings:
- The abscess was located anterior and lateral to the urethra, separate from the TOT.
- Magnetic resonance imaging (MRI) delineated the abscess extent into the retropubic space.
- Surgical vaginal drainage resolved pain but resulted in SUI recurrence.
Implications:
- This case highlights a rare but serious complication of Bulkamid injections.
- It underscores the importance of vigilant monitoring for abscess formation after bulking agent use.
- Further research may be needed to assess the long-term safety profile of Bulkamid, especially in patients with prior pelvic reconstructive surgery.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Microbiota of the Urogenital Tract
